ARQT — Arcutis Biotherapeutics, Inc.

Summary of Arcutis Biotherapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenues: $99.2 million for Q3 2025, representing a 122% increase year-over-year and a 22% sequential growth.
• Total Prescriptions for ZORYVE: Increased by 13% compared to Q2 and by 92% versus Q3 2024, reaching over 17,000 weekly prescriptions on a rolling 4-week average.
• Net Income: $7.4 million, a significant turnaround from a net loss of $41.5 million in Q3 2024 and a loss of $15.9 million in Q2 2025.
• Cash and Marketable Securities: $191 million as of September 30, 2025, with a cash burn from operations of $1.8 million.
• Debt: Total debt of $108.5 million, with an option to withdraw an additional $100 million.

2. Strategic Updates and Business Highlights

• ZORYVE Growth: Continued strong demand for ZORYVE, a topical agent for chronic inflammatory skin diseases, with successful launches in new indications (e.g., foam formulation for scalp and body psoriasis).
• Pipeline Development: Introduction of ARQ-234, a novel biologic for atopic dermatitis, with plans to initiate a Phase I trial.
• Market Positioning: ZORYVE is positioned as a safer alternative to traditional topical corticosteroids, with a focus on expanding into primary care and pediatric markets.
• Life Cycle Management: Efforts to explore new indications for ZORYVE, including pediatric applications and additional inflammatory skin conditions.

3. Forward Guidance and Outlook

• Cash Flow Breakeven: Expected to achieve cash flow breakeven in Q4 2025, accelerated by strong ZORYVE sales growth and expense discipline.
• 2026 Revenue Guidance: Full-year net product revenues projected between $455 million and $470 million, reflecting continued strong demand.
• Market Share Goals: Aiming for ZORYVE to capture 15% to 20% of the topical corticosteroid market over time, with ongoing efforts to convert prescriptions from steroids to non-steroidal alternatives.

4. Bad News, Challenges, or Points of Concern

• Limited Gross to Net Improvement: Anticipated only modest improvements in gross to net rates in Q4 2025 compared to Q3 due to historical trends.
• Competitive Pressures: The ongoing shift in dermatology towards non-steroidal treatments may face challenges from entrenched use of topical corticosteroids and insurance step-through requirements.
• Market Dynamics: The transition from topical steroids to non-steroidal treatments is expected to take time, with historical analogs suggesting a 5-10 year timeframe for significant market shifts.

5. Notable Q&A Insights

• Conversion of Topical Steroids: The call emphasized the importance of the ongoing shift towards topical steroid stewardship, with dermatologists increasingly recognizing the adverse effects of prolonged steroid use.
• ARQ-234 Development: Differentiation from Eli Lilly's discontinued CD200R agonist program was highlighted, focusing on ARQ-234's unique structure and potential advantages.
• Incremental Data Generation: The potential for ZORYVE to address challenging patient populations (e.g., nail psoriasis) was discussed, with expectations that strong data could drive increased adoption.
• Market Access and Commercial Strategy: The company is focused on expanding market access and leveraging its sales force to enhance ZORYVE's penetration in primary care and pediatric settings.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Arcutis Biotherapeutics' performance and outlook for Q3 2025.